In our pursuit of being at the forefront of innovation, we are delighted to share the news of our second successful DCP closure for Desmopressin. While the demand has been extraordinary, we are excited to offer a select few MAs to potential partners who wish to embark on this remarkable journey with us.
Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. The brand sold $116Mn globally in 2022, according to IQVIA.
Adalvo is one of the very few companies working on this complex niche peptide product which underpins Adalvo's robust R&D strengths and capabilities, and demonstrates our ability to continuously offer highly differentiated, value-added niche products to our partners.
Partner Up Now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.